Inspirna
Michael is currently a research analyst at Sands Capital, a leading growth-oriented investment firm. Since joining in 2011, he has invested in life sciences businesses across the private and public markets, with a primary focus on therapeutics. In addition to Inspirna, he also serves on the board of Prilenia Therapeutics. Michael earned a B.S. in Commerce from the University of Virginia in 2011 and has been a CFA charterholder since 2015.
This person is not in the org chart
This person is not in any offices
Inspirna
Inspirna, Inc. (formerly known as Rgenix, Inc.) is developing first-in-class drugs that target key pathways in cancer progression.